MedTrace Logo

Drugs Brain and Behavior (DDP)

NCT04642820 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2025-01-09

Study results available
· View outcomes & findings →

Summary

In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.

Conditions

  • Stimulant Use

Interventions

DRUG

Methamphetamine

Participants will be given 20 mg of Methamphetamine.

DRUG

placebo oral tablet

Participants will be given a placebo capsule that will only contain lactose.

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Chicago

    lead OTHER

Principal Investigators

  • Harriet de Wit · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2023-10-01
Completion
2024-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04642820 on ClinicalTrials.gov